8-K: Xeris Biopharma 2026 Annual Meeting Voting Results

Xeris Biopharma Holdings, Inc. successfully concluded its 2026 Annual Meeting with the election of directors and ratification of its auditor.

Summary

• The 2026 Annual Meeting was held on June 4, 2026, with a quorum of 128,268,073 shares present out of 172,625,762 outstanding.
• Dawn Halkuff and John Johnson were elected as Class II directors until the 2029 Annual Meeting.
• Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
• The advisory vote on executive compensation (Say-on-Pay) was approved by stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the filing reports routine administrative outcomes of an annual meeting without material changes to strategy or financial outlook.

Positives

• Successful quorum achieved with approximately 74.3% of outstanding shares represented.
• Strong support for the appointment of Ernst & Young LLP with 125,789,818 votes in favor.
• Approval of executive compensation indicates shareholder alignment with current management incentives.

Negatives

• Significant broker non-votes (40,780,330) were recorded for director elections and executive compensation, reflecting lower retail engagement.
• John Johnson received a higher number of withhold votes (34,822,666) compared to Dawn Halkuff (24,906,166).

Risks

• Potential for future shareholder dissatisfaction if executive compensation continues to face scrutiny, as evidenced by the withhold votes in director elections.

Future Outlook

No specific forward-looking financial guidance was provided in this filing, as it was limited to the results of the annual meeting.

Industry Context

StockSavvy.ai notes that this filing represents standard corporate governance procedures for a mid-cap biotechnology firm, showing stability in board composition and auditor relations.

Comparison to Industry Standards

• The ratification of Ernst & Young LLP is consistent with standard practices for Nasdaq-listed biopharma companies.
• The use of plurality voting for directors is a common governance structure among Delaware-incorporated entities.

Corporate Governance

Stakeholder Impact

• Shareholders maintain continuity in board leadership and audit oversight.
• Executive management retains shareholder approval for compensation structures.

Next Steps

• Directors Dawn Halkuff and John Johnson will serve until the 2029 Annual Meeting.
• Ernst & Young LLP will proceed as the independent auditor for the 2026 fiscal year.

Key Dates

Keywords

Xeris Biopharma, XERS, Annual Meeting, Proxy Voting, Corporate Governance, Biotechnology